News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Metastatix, Inc. Closes $35 Million Series B Financing


10/16/2007 4:25:33 PM

Metastatix, an emerging pharmaceutical company focused on the development of small molecule therapeutics, announced today it has secured $35 million in Series B financing. The new round of funding primarily will be used to conduct clinical trials of the company's lead candidate, MSX-122, in cancer patients and to advance the company's development programs in inflammation and HIV infection.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES